Abstract:Abstract Tumor-associated macrophages (TAMs) are the predominant immune cells within the tumor microenvironment (TME), and their phenotypic modulation is influenced by environmental cues in the TME. In early tumors, TAMs adopt a pro-inflammatory M1-like phenotype, characterized by the secretion of immunogenic cytokines and the ability to kill cancer cells, thus opposing tumorigenesis. However, as tumors progress, TAMs mainly transition to an anti-inflammatory M2-like phenotype, promoting angiogenesis, suppressing anti-tumor immunity, and supporting metastasis. Importantly, a high M2-like/M1-like TAM ratio correlates with poor survival and decreased treatment responses.Despite the significance of TAMs, the molecular mechanisms driving their pro-tumorigenic M2-like phenotype remain unclear. One potential mechanism is metabolic reprogramming, where, traditionally, M1 macrophages favor glycolysis, and M2 macrophages rely on oxidative phosphorylation. However, this paradigm is primarily derived from in vitro experiments using well-defined polarization cocktails, which may not accurately replicate the complex TME. For instance, while in in vitro experiments IL4 and IL13 can induce oxidative phosphorylation and an M2-like phenotype, these cytokines do not seem essential for M2-like TAM polarization in vivo.Our studies reveal that, relative to M1-like TAMs, M2-like TAMs exhibit heightened glycolysis, intracellular lactate accumulation, and increased histone lysine lactylation - an epigenetic mark directly stimulated by lactate. Importantly, we demonstrate that TAM glycolysis and the M2-like phenotype are positively associated with hypoxia within a single tumor (GEM model and human tumors) and across various tumor types (syngeneic models). Inhibition of glycolysis-stimulated lactate production in TAMs through myeloid cell-specific deletion of lactate dehydrogenase A (mLdha-/-) reduces the M2-like:M1-like TAM ratio. This intervention increases tumor-infiltrating CD8+ T cells and reduces tumor growth in pre-clinical models, particularly in highly hypoxic environments. Moreover, to exclude the role of cancer cell-derived lactate on TAMs’ phenotypic changes, we reduced glycolysis in cancer cells by deleting pyruvate kinase muscle isozyme M2 (PKM2). This resulted in decreased lactate production and suppressed tumor growth. However, the M2/M1 ratio remained unaffected, suggesting that the intrinsic lactate production by TAMs is crucial for their phenotype modulation.Our findings underscore the pivotal role of hypoxia-induced glycolysis and lactate production in TAMs, shaping their M2-like phenotype and impacting tumor progression. This understanding not only advances our knowledge of macrophage metabolism and phenotype dynamics in the context of cancer but also in other diseases. Citation Format: Katarzyna Kurylowicz, Kasturi Chakraborty, Chang Cui, Gustavo Gastão Davanzo, Guolin Zhou, Xu Anna Tang, Kelly Q. Schoenfelt, Natalie Pulliam, Catherine A. Reardon, Swati Kulkarni, Tomas Vaisar, Pedro M. Moraes-Vieira, Yingming Zhao, Lev Becker. Glycolysis-stimulated lactate production by tumor-associated macrophages promotes their M2-like phenotype [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 2686.

Abstract 159: LYVE-1-expressing macrophages modulate the hyaluronan-containing extracellular matrix in the mammary stroma and contribute to mammary tumor growth

Abstract PO4-25-05: LYVE-1 expressing macrophages modulate the extracellular matrix and contribute to mammary tumor growth

Abstract 6533: Pivotal role of specific LYVE1+ tissue resident macrophages in PDAC progression & immunotherapy resistance

Abstract SY37-03: Leveraging the complexities of tumor associated macrophages for effective anti-cancer therapy

Abstract 6628: Mapping the spatial and molecular determinants of macrophage heterogeneity in breast cancer

LYVE1+ macrophages of murine peritoneal mesothelium promote omentum-independent ovarian tumor growth

Abstract 1348: LMW-E induction and crosstalk with immune cells potentiates local immune responses leading to an immunosuppressive microenvironment at the early stages of breast tumorigenesis in mouse models

Abstract 293: Distinctive roles of mammary adipomes in breast cancer progression: Insights from functional analysis and differential gene expression

Abstract PO1-25-01: LMTK3 promotes macrophage M2 polarisation and suppresses monocyte infiltration in breast cancer by altering the proteomic cargo of exosomes

The shedded ectodomain of Lyve-1 expressed on M2-like tumor-associated macrophages inhibits melanoma cell proliferation

Integrated multiomics analysis unveils how macrophages drive immune suppression in breast tumors and affect clinical outcomes

Abstract 2686: Glycolysis-stimulated lactate production by tumor-associated macrophages promotes their M2-like phenotype

Abstract 1105: Tumor Cells of the Early Metastatic Process Show Up Regulation of Cytokine Genes Involved in Migration of Inflammatory Cells

Abstract 5568: Understanding the role of immune exclusion in mammary tumor growth

Abstract 186: Tumor exosome-macrophage interactions: The role of tumor-associated glycans and scavenger receptor class A

Defining and targeting macrophage heterogeneity in the mammary gland and breast cancer

Abstract A122: Deciphering macrophage targeting cancer immunotherapies using a novel in vitro assay modelling the tumor microenvironment

Abstract PR011: DCIS-associated myoepithelial cells drive tumor progressive inflammation through up-regulation of integrin αvβ6

Abstract B019: Identify features of fibroblast and macrophage which regulate metastasis of triple-negative breast cancer

Abstract 3959: Unraveling the anti-tumor partnership of CD169+ macrophages and CD8+ T cells in a preclinical breast cancer model

Abstract 5086: Legumain-contained Exosomes Mediate Remodeling of Tumor Extracellular Matrix and Protumor Effects of TAMs